about
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in ChordomaPhase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialA phase i study of DMS612, a novel bifunctional alkylating agent.Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerPhase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.Pharmacotherapy in cancer patients with HIV/AIDSClove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells.A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).Hepatotoxicity and metabolism of trabectedin: a literature review.Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer.Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrewsPoly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage.A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridinePlasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogsA quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cellsFunctional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assayHuman mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humansPreclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Mass balance studies, with a focus on anticancer drugs.Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometryLC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasmaA Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymeraseEffect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies
P50
Q30278895-1CB7AB03-33E6-4532-AF1A-945C32452517Q33391851-9F10C47D-2F66-4585-9CFB-C848C4475405Q33411822-70AB36ED-22E2-4CB0-9D5F-6A44DD908E92Q33419113-8FF96DD0-3187-421B-A8B9-F870F58E8D79Q33429434-CC59F761-9BA2-4B2C-A0A4-0FC1F40E29DFQ33437008-16B67080-1563-451A-AC6E-E2ADFEDBF96EQ33769429-CDE003E8-6EBF-48A2-911F-90D12B701EA5Q33832257-3A54E0DE-F8BA-48A9-8EA6-7FB83B4DB7EFQ33881799-587A29E9-CFEF-42C3-A85A-C01D3BD60619Q34044000-02E1AA61-F88A-400A-AAC3-EA22F5DAC489Q34053767-D5BC5688-2D2B-426D-AABD-0453E5D4377FQ34194110-050E6F10-288D-4C6D-B322-02DA8050FC78Q34195332-BF887159-AA3A-47E7-8F31-0D995F7A6A49Q34266295-6E4BF3EB-7042-43CD-A43E-94F3731482D2Q34283338-A545C877-68B0-4137-A6FD-B11DE6B815DFQ34409335-A24C5D86-0626-44B0-9B07-5EE2303014F9Q34555733-D8E4795D-5D92-4B87-8D3D-3F8026953B0BQ34560520-F7709825-42BE-4147-9F4F-49ECEF83F8D8Q34764877-18583FD3-0822-4F20-AF31-E644823A94F6Q34807270-F624DA33-F57B-4E3A-99EC-1AE1D82698DBQ34982593-586D9B06-F634-44C1-B4CD-D7AA3A3AD211Q34987777-F59389F9-3A13-4066-9CC5-01EC401F9618Q35130668-9E0AC803-AB8C-4AFE-ABD8-18F6692B9F80Q35572215-7DFB6032-16CC-4636-A003-B40300D42AD1Q35745041-18BEF9CD-ABB1-4670-97E0-E7481BF34490Q35799909-B1808CCF-63A8-4D50-935B-C445C8506358Q35830723-F0E2A841-C8CB-432D-9116-A6B29A5527ACQ35884220-743203A0-0770-4F70-A855-B9D740E9AA4AQ35984176-8AA98083-12B2-4384-AF5F-C3230F3DB21DQ36002546-BCC10DE0-7BA0-4A64-918F-7C17A165EDFEQ36070627-EAFE184F-0779-4A0E-BE28-2DD815BBFFA6Q36080621-2F39F56A-ACC3-427C-BF21-96E1EF1C0BE9Q36243653-718BD5D1-06E9-4B3F-BF88-77C86EB1AEDAQ36375326-AC2D701A-5816-4545-9A57-FC63499F85F8Q36508219-9D67E50C-5E82-4C35-A080-A7B8146E1FC3Q36619557-515A4595-A42D-4312-AF4D-E27EF7165408Q36874638-05137DF2-9F86-4501-996A-3BF350DF89BEQ36988077-465CFE55-54E1-412E-97BD-D3BB3CB2ECB4Q37080221-10386BC8-EDA8-4632-96D9-3CD72F2900E4Q37166427-96C12DAD-EB53-4F53-9EE0-730286750C95
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jan H Beumer
@ast
Jan H Beumer
@en
Jan H Beumer
@es
Jan H Beumer
@fr
Jan H Beumer
@nl
Jan H Beumer
@sl
type
label
Jan H Beumer
@ast
Jan H Beumer
@en
Jan H Beumer
@es
Jan H Beumer
@fr
Jan H Beumer
@nl
Jan H Beumer
@sl
prefLabel
Jan H Beumer
@ast
Jan H Beumer
@en
Jan H Beumer
@es
Jan H Beumer
@fr
Jan H Beumer
@nl
Jan H Beumer
@sl
P106
P21
P31
P496
0000-0002-8978-9401